Script section containing code for Liveperson Chat Solution

Hoover's - A D&B Company - We Make It Easier
Buy Reports For This Company

Affymax, Inc.
Palo AltoCA United States
  (NASDAQ: AFFY)

btn-overview-2btn-people-1btn-competition-1btn-financials-1

Company Description

Affymax is training peptides to give red blood cells a pep talk. The biotechnology firm is researching and developing drugs based upon peptides, which can help regulate biological processes. Its leading drug candidate, Omontys (peginesatide), was approved by the FDA in 2012 as a treatment for anemia due to chronic kidney disease. Omontys is a synthetic peptide-based erythropoietin (EPO) agent, designed to stimulate red blood cell production like EPO itself. Affymax believes Omontys, which was developed and commercialized through a partnership with Japan's Takeda Pharmaceutical, will prove to be cheaper and longer lasting than the EPO stimulants currently used on dialysis patients.

4001 Miranda Ave.Phone: 650-812-8700http://www.affymax.com
Palo AltoCA 94304Fax: 650-424-0832Map Map This Company
United States

Try a Full Premium Subscription

Access over 85 million companies
Call (866) 443-3939 or

btn-free-trial

Prepare for your Sales call

Try a Small Business Subscription
Starting $89 per month

btn-subscribe-now

Affymax, Inc. Rankings

Russell 2000 (June 2011)

Executives

32 executives listed for Affymax, Inc.'s Palo Alto, CA location.
ChairmanHollings RentonE-mail
CEO and DirectorJohn OrwinE-mail
CFOHerb CrossE-mail

More Affymax, Inc. Executives

Financials

Company TypePublic - NASDAQ: AFFY Single Location
Fiscal Year-EndDecember
2011 Employees130
More Affymax, Inc. Financials
D&B logoDNBi

Leverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Affymax, Inc. now.

  • Reduce risk.
  • Drive greater profitability.
  • Increase cash flow.
Get a Credit Report Now

Sponsored Links